OCULAR THERAPEUTIX, INC Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
OCULAR THERAPEUTIX, INC (OCUL) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $13.24 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-02-05
- OCULAR THERAPEUTIX, INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $13.24, a 64.06% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $8.07, a 6.49% decline from fiscal 2023.
- OCULAR THERAPEUTIX, INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $8.63, a 2.13% increase from fiscal 2022.
- OCULAR THERAPEUTIX, INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $8.45, a 26.39% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $13.24 10-K · filed 2026-02-05 |
| 2024-12-31 | $8.07 10-K · filed 2025-03-03 |
| 2023-12-31 | $8.63 10-K · filed 2024-03-11 |
| 2022-12-31 | $8.45 10-K · filed 2023-03-06 |
| 2021-12-31 | $11.48 10-K · filed 2022-02-28 |
| 2020-12-31 | $5.84 10-K · filed 2021-03-11 |
| 2019-12-31 | $6.84 10-K · filed 2020-03-12 |
| 2018-12-31 | $10.83 10-K · filed 2019-03-07 |
| 2017-12-31 | $9.12 10-K · filed 2018-03-08 |
| 2016-12-31 | $13.72 10-K · filed 2017-03-10 |
| 2015-12-31 | $16.61 10-K · filed 2016-03-10 |
| 2014-12-31 | $5.56 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |